The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
Plans underway to expand screening capacity by 50% for greater accessibility
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
Subscribe To Our Newsletter & Stay Updated
